FDA Grants Fast Track Status to Triumvira’s T-cell Therapy TAC01-CD19 for DLBCL
News
The U.S. Food and Drug Administration (FDA) has granted fast track designation to Triumvira Immunulogics‘ investigational T-cell therapy TAC01-CD19 for the treatment of relapsed or refractory diffuse large B-cell lymphoma ... Read more